Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Heather G Jørgensen; Elaine K Allan; Joanne C Mountford; Linda Richmond; Simon Harrison; Moira A Elliott; Tessa L Holyoake

doi:10.1016/j.exphem.2005.05.020

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Heather G Jørgensen, Elaine K Allan, Joanne C Mountford, Linda Richmond, Simon Harrison, Moira A Elliott, Tessa L Holyoake

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.

Original language	English
Pages (from-to)	1140-6
Number of pages	7
Journal	Experimental Hematology
Volume	33
Issue number	10
DOIs	https://doi.org/10.1016/j.exphem.2005.05.020
Publication status	Published - 2005

Keywords

antigens
antineoplastic agents
apoptosis
bryostatins
drug antagonism
hematopoietic stem cells
leukemia
macrolides
piperazines
protein kinase C
pyrimidines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.exphem.2005.05.020

Cite this

@article{d61614c95cdc40758d4d8e4c1b6b9b72,

title = "Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate",

abstract = "In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.",

keywords = "antigens, antineoplastic agents, apoptosis, bryostatins, drug antagonism, hematopoietic stem cells, leukemia, macrolides, piperazines, protein kinase C, pyrimidines",

author = "J{\o}rgensen, {Heather G} and Allan, {Elaine K} and Mountford, {Joanne C} and Linda Richmond and Simon Harrison and Elliott, {Moira A} and Holyoake, {Tessa L}",

year = "2005",

doi = "10.1016/j.exphem.2005.05.020",

language = "English",

volume = "33",

pages = "1140--6",

journal = "Experimental Hematology ",

issn = "0301-472X",

number = "10",

}

TY - JOUR

T1 - Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

AU - Jørgensen, Heather G

AU - Allan, Elaine K

AU - Mountford, Joanne C

AU - Richmond, Linda

AU - Harrison, Simon

AU - Elliott, Moira A

AU - Holyoake, Tessa L

PY - 2005

Y1 - 2005

N2 - In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.

AB - In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.

KW - antigens

KW - antineoplastic agents

KW - apoptosis

KW - bryostatins

KW - drug antagonism

KW - hematopoietic stem cells

KW - leukemia

KW - macrolides

KW - piperazines

KW - protein kinase C

KW - pyrimidines

U2 - 10.1016/j.exphem.2005.05.020

DO - 10.1016/j.exphem.2005.05.020

M3 - Article

C2 - 16219536

SN - 0301-472X

VL - 33

SP - 1140

EP - 1146

JO - Experimental Hematology

JF - Experimental Hematology

IS - 10

ER -

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this